Tirzepatide Titration to Reduce Side Effects in Individuals With Obesity

What Was Tested

The trial (not phased) is built around Tirzepatide.

It had two arms (groups): Per-label arm (Control) (active comparator) and Flexible titration arm (Intervention) (experimental).

The registry classes the interventions as drug.

More on the Plan

Current labeling recommends a fixed titration schedule that does not account for individual differences in symptom tolerance.

Evidence supporting individualized titration strategies in obesity treatment remains limited.

All participants will attend study visits over 76 weeks for assessment of treatment persistence, weight change, gastrointestinal tolerability, safety, and adherence.

The primary outcome is time to discontinuation of the treatment regimen over 76 weeks, analyzed as restricted mean time on treatment.

Who Took Part

Enrollment: 68 planned participants were the target.

It was open to people of any sex aged from 18 years up to 100 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Adults aged 18 years and older. A diagnosis of obesity (BMI ≥ 27 kg/m2) at screening with self-reported unsuccessful dietary efforts to lose weight. Able to understand and sign the consent form. Able to undergo DEXA scan.

The full record lists 5 inclusion and 26 exclusion criteria; among the exclusions: A self-reported change in body weight \>5 kg (11 lbs) within 90 days before screening irrespective of medical records; treatment with any medication for the indication of obesity within the past 90 days before screening; uncontrolled thyroid disease, defined as thyroid stimulating hormone \>6.0 miu/l or \<0.4 miu/l as measured by the central laboratory at screening.

How the Study Was Run

Design: randomized, parallel-group and open-label.

Random assignment meant chance, not the researchers, decided who got Tirzepatide and who got the comparison, which limits bias.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Everyone knew when Tirzepatide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

It started in 2026-05-15 with completion listed for 2029-05-15.

It ran at 1 site in Kuwait.

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Time to discontinuation of the treatment regimen (time frame: Randomization to Week 76).

It also tracked 34 secondary outcomes, for example Exposure-adjusted rate of vomiting episodes assessed using the Modified Index of Nausea, Vomiting, and Retching (M-INVR), Incidence, frequency, and duration of vomiting assessed using the MASCC Antiemesis Tool - Modified Index of Nausea and Vomiting (M-INVR), Change in body weight, Proportion of participants remaining on active study medication, Change in glycated hemoglobin (HbA1c) and Change in lean body mass assessed by dual-energy X-ray absorptiometry (DEXA).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of Tirzepatide in 68 people.

It is still recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.